B Cell Chronic Lymphocytic Leukemia | List of Frontiers open access articles

Original Research

Published on 27 Oct 2016

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells

in Cancer Immunity and Immunotherapy

Diego Sánchez-Martínez
Pilar M. Lanuza
Natalia Gómez
Aura Muntasell
Elisa Cisneros
Manuela Moraru
Gemma Azaceta
Alberto Anel
Luis Martínez-Lostao
Martin Villalba

Frontiers in Immunology

doi 10.3389/fimmu.2016.00454

5,467 views
27 citations

Review

Published on 07 Nov 2022

CD160 receptor in CLL: Current state and future avenues

in Cancer Immunity and Immunotherapy

Loubna Oumeslakht
Abdel-ilah Aziz
Armand Bensussan
Sanae Ben Mkaddem

Frontiers in Immunology

doi 10.3389/fimmu.2022.1028013

6,369 views
13 citations

Case Report

Published on 17 Jan 2022

Case Report: Long-Term Survival of a Dog With Chronic Lymphocytic Leukemia Treated With Chlorambucil, Prednisolone, and Imatinib

in Veterinary Clinical, Anatomical, and Comparative Pathology

Ga-Won Lee
Min-Hee Kang
Jin-Ha Jeon
Doo-Won Song
Woong-Bin Ro
Heyong-Seok Kim
Hee-Myung Park

Frontiers in Veterinary Science

doi 10.3389/fvets.2021.625527

24,299 views
3 citations

Review

Published on 08 Jan 2021

The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche

in Stem Cell Research

Paul Takam Kamga
Riccardo Bazzoni
Giada Dal Collo
Adriana Cassaro
Ilaria Tanasi
Anna Russignan
Cristina Tecchio
Mauro Krampera

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2020.599276

15,253 views
44 citations

Review

Published on 03 Apr 2018

Chemotactic Cues for NOTCH1-Dependent Leukemia

in Cancer Immunity and Immunotherapy

Erich Piovan
Valeria Tosello
Alberto Amadori
Paola Zanovello

Frontiers in Immunology

doi 10.3389/fimmu.2018.00633

8,059 views
16 citations

Original Research

Published on 16 Jun 2014

TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20+ Antibody-Secreting Cells

in B Cell Biology

Hussein Ghamlouch
Hakim Ouled-Haddou
Aude Guyart
Aline Regnier
Stéphanie Trudel
Jean-François Claisse
Vincent Fuentes
Bruno Royer
Jean-Pierre Marolleau
Brigitte Gubler

Frontiers in Immunology

doi 10.3389/fimmu.2014.00292

11,157 views
13 citations

Original Research

Published on 25 Jun 2024

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

in Cancer Immunity and Immunotherapy

Song Li
Dianze Chen
Yanan Yang
Huiqin Guo
Dandan Liu
Nana Sun
Xing Bai
Kaili Wang
Tengfei Li
Guanghui Li

Frontiers in Immunology

doi 10.3389/fimmu.2024.1398508

4,061 views
1 citation

Articles

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells

CD160 receptor in CLL: Current state and future avenues

Case Report: Long-Term Survival of a Dog With Chronic Lymphocytic Leukemia Treated With Chlorambucil, Prednisolone, and Imatinib

The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche

Chemotactic Cues for NOTCH1-Dependent Leukemia

TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20+ Antibody-Secreting Cells

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38